Inflammatory Bowel Disease, New England Journal of Medicine, vol.361, issue.21, pp.2066-78, 2009. ,
DOI : 10.1056/NEJMra0804647
Crohn's disease. Lancet, Nov, vol.3380, issue.9853, pp.1590-605, 2012. ,
Ulcerative Colitis, New England Journal of Medicine, vol.365, issue.18, pp.1713-1738, 2011. ,
DOI : 10.1056/NEJMra1102942
URL : https://hal.archives-ouvertes.fr/hal-01707812
Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study, Gastroenterology, vol.135, issue.4, pp.1106-1119, 2008. ,
DOI : 10.1053/j.gastro.2008.06.079
Crohn's disease complicated by strictures: a systematic review, Gut, vol.3, issue.Suppl. 8, pp.1072-84, 2013. ,
DOI : 10.1016/j.crohns.2009.06.001
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort, Gastroenterology, vol.139, issue.4, pp.1147-55, 2010. ,
DOI : 10.1053/j.gastro.2010.06.070
An Overview of the Natural History of Inflammatory Bowel Diseases, Digestive Diseases, vol.32, issue.4, pp.320-327, 2014. ,
DOI : 10.1159/000358131
Review article: the practical management of acute severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.25, issue.6 Suppl., pp.482-513, 2016. ,
DOI : 10.1159/000170882
Surgery for adult Crohn's disease: what is the actual risk?, Gut, vol.60, issue.9, pp.1178-81, 2011. ,
DOI : 10.1136/gut.2010.234617
Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study, Aliment Pharmacol Ther, p.2017 ,
Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in ??rebro, Sweden, 1963-2010, Alimentary Pharmacology & Therapeutics, vol.7, issue.8, pp.748-757, 1963. ,
DOI : 10.2214/ajr.117.2.292
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review, The American Journal of Gastroenterology, vol.104, issue.4, pp.674-84, 2011. ,
DOI : 10.1038/ajg.2008.38
Review article: loss of response to anti-TNF treatments in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.58, issue.9, pp.987-95, 2011. ,
DOI : 10.1136/gut.2008.157339
Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol, Feb, vol.13, issue.2, pp.336-344, 2015. ,
An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.13, issue.2 ,
DOI : 10.1016/j.cgh.2014.07.041
Review article: dose optimisation of infliximab for acute severe ulcerative colitis, Aliment Pharmacol Ther, vol.45, issue.5, pp.617-630, 2017. ,
Preliminary report: cyclosporin in treatment of severe active ulcerative colitis, The Lancet, vol.336, issue.8706, 1990. ,
DOI : 10.1016/0140-6736(90)91521-B
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980. ,
DOI : 10.1016/S0140-6736(80)92767-1
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders, Journal of Crohn's and Colitis, vol.124, issue.76, pp.649-670, 2017. ,
DOI : 10.1016/S0016-5085(03)00171-9
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management, J Crohns Colitis, vol.11, issue.1, pp.20173-20198 ,
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006. ,
DOI : 10.1136/gut.2005.082909
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54, 2010. ,
DOI : 10.1136/gut.2009.183095
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis, Gastroenterology, vol.149, issue.2, pp.350-355, 2015. ,
DOI : 10.1053/j.gastro.2015.04.016
Crohn's and Colitis Organisation (ECCO) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, J Crohns Colitis. Feb, vol.4, issue.1, pp.7-27, 2010. ,
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases, Gastroenterology, vol.153, issue.3, pp.835-857, 2017. ,
DOI : 10.1053/j.gastro.2017.07.031
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies Ann Intern Med, pp.573-577, 2007. ,
Analysis of Survival Data under the Proportional Hazards Model, International Statistical Review / Revue Internationale de Statistique, vol.43, issue.1, pp.1-45, 1975. ,
DOI : 10.2307/1402659
Regression Models and Life-Tables, Journal of the Royal Statistical Society. Series B (Methodological), vol.34, pp.2-187, 1972. ,
DOI : 10.1007/978-1-4612-4380-9_37
Applied logistic regression, Wiley Series in Probability and Mathematical Statistics, 2000. ,
DOI : 10.1002/0471722146
National trends in intestinal resection for Crohn???s disease in the post-biologic era, International Journal of Colorectal Disease, vol.99, issue.5, 2013. ,
DOI : 10.1002/bjs.8698
Small bowel resection rates in Crohn??s disease and the indication for surgery over time: Experience from a large tertiary care center, Inflammatory Bowel Diseases, vol.136, issue.5, pp.830-835, 2010. ,
DOI : 10.1053/j.gastro.2008.10.051
Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit, Alimentary Pharmacology & Therapeutics, vol.60, issue.Suppl. 2, pp.935-980, 2013. ,
DOI : 10.1136/gut.2010.216895
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects, Journal of Crohn's and Colitis, vol.31, issue.36, pp.355-66, 2010. ,
DOI : 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management, Alimentary Pharmacology & Therapeutics, vol.104, issue.Suppl. 1, pp.30-51, 2016. ,
DOI : 10.1038/ajg.2009.372
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, Lancet, vol.380, issue.9857, pp.1909-1924, 2012. ,
Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT), BMJ Open, vol.4, issue.4, p.5091, 2014. ,
DOI : 10.1136/bmjopen-2014-005091
Golimumab for the treatment of ulcerative colitis, Expert Opinion on Biological Therapy, vol.56, issue.2, pp.879-886 ,
DOI : 10.1111/j.1365-2036.2009.04027.x
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic???pharmacodynamic modeling of biologics, Expert Opinion on Drug Metabolism & Toxicology, vol.52, issue.7, pp.803-815, 2009. ,
DOI : 10.1208/aapsj0902020
Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease, Gastroenterology, vol.149, issue.6, pp.1564-1574, 2015. ,
DOI : 10.1053/j.gastro.2015.07.002
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial, Gut, vol.10, issue.(Suppl 1), pp.1126-1157, 2016. ,
DOI : 10.1016/j.cgh.2012.06.032
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease, New England Journal of Medicine, vol.350, issue.9, pp.876-85, 2004. ,
DOI : 10.1056/NEJMoa030815
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005. ,
DOI : 10.1056/NEJMoa050516
Mo1878 Comparison of Accelerated Infliximab Induction vs Standard Induction Treatment in Acute Severe Ulcerative Colitis, Gastroenterology, vol.150, issue.4, pp.803-843, 2016. ,
DOI : 10.1016/S0016-5085(16)32720-2
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.12, pp.2247-59, 2014. ,
DOI : 10.1016/j.cgh.2012.06.032
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study), Scandinavian Journal of Gastroenterology, vol.19, issue.2, pp.431-471, 2009. ,
DOI : 10.3109/00365529609004876
Risk Factors for Surgery and Postoperative Recurrence in Crohn???s Disease, Annals of Surgery, vol.231, issue.1, pp.38-45, 2000. ,
DOI : 10.1097/00000658-200001000-00006
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.13, issue.3, pp.531-539, 2015. ,
DOI : 10.1016/j.cgh.2014.07.055
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab, Gastroenterology, vol.137, issue.4, pp.1250-60, 2009. ,
DOI : 10.1053/j.gastro.2009.06.061
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease, Gastroenterology, vol.153, issue.3, pp.827-834, 2017. ,
DOI : 10.1053/j.gastro.2017.07.032
Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy, Clinical Gastroenterology and Hepatology, vol.13, issue.6, pp.1118-1142 ,
DOI : 10.1016/j.cgh.2014.12.026
514 Higher Infliximab Trough Levels Are Associated With a Higher Rate of Perianal Fistula Healing in Patients With Crohn's Disease, Gastroenterology, vol.150, issue.4, 2017. ,
DOI : 10.1016/S0016-5085(16)30460-7
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.11, issue.12, pp.1293-1302, 2016. ,
DOI : 10.1016/j.cgh.2012.10.020
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-?? drugs for refractory Crohn's disease, Journal of Crohn's and Colitis, vol.30, issue.3, pp.77-85, 2012. ,
DOI : 10.1111/j.1365-2036.2009.04033.x
Individualised therapy is more cost-effective than dose intensification in patients with Crohn???s disease who lose response to anti-TNF treatment: a randomised, controlled trial, Gut, vol.356, issue.Suppl 1, pp.919-946, 2014. ,
DOI : 10.1016/S0140-6736(00)02871-3
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study, Gut, vol.46, issue.(Suppl 6), pp.249-55, 2016. ,
DOI : 10.1016/j.cyto.2009.02.001
Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease, Trends in Molecular Medicine, vol.23, issue.4, pp.362-374 ,
DOI : 10.1016/j.molmed.2017.02.002
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines, American Journal of Physiology-Gastrointestinal and Liver Physiology, vol.67, issue.3, pp.155-62 ,
DOI : 10.3748/wjg.v20.i1.91
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease, Journal of Crohn's and Colitis, vol.374, issue.7, pp.885-893, 2017. ,
DOI : 10.1056/NEJMoa1513248
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT??? Registry, The American Journal of Gastroenterology, vol.31, issue.9, pp.1409-1431, 2012. ,
DOI : 10.3899/jrheum.100347
High-Dose Infliximab Therapy in Crohn's Disease: Clinical Experience, Safety, and Efficacy, Journal of Crohn's and Colitis, vol.109, issue.11, pp.266-75 ,
DOI : 10.1038/ajg.2014.146
A Simple Classification of Crohn??s Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998, Inflammatory Bowel Diseases, vol.111, issue.1, pp.8-15, 1998. ,
DOI : 10.1053/gast.1996.v111.pm8780560
Longterm evolution of disease behavior of Crohn's disease, Inflamm Bowel Dis, 2002. ,
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis, New England Journal of Medicine, vol.317, issue.26, pp.1625-1634, 1987. ,
DOI : 10.1056/NEJM198712243172603
Cortisone in Ulcerative Colitis, BMJ, vol.2, issue.4947, pp.1041-1048, 1955. ,
DOI : 10.1136/bmj.2.4947.1041
Developing an instrument to 42 ,
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus, Alimentary Pharmacology & Therapeutics, vol.12, issue.6, pp.801-813, 2017. ,
DOI : 10.1016/j.cgh.2013.07.022
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials, Gut, vol.59, issue.(Suppl), pp.1447-55, 2016. ,
DOI : 10.1136/gut.2009.194159